Bio

Professional Education


  • Doctor of Philosophy, Oregon Health Sciences University (2018)
  • Master of Medicine, Wuhan University (2012)

Publications

All Publications


  • Induced Pluripotent Stem Cell-Based Cancer Vaccines FRONTIERS IN IMMUNOLOGY Ouyang, X., Telli, M. L., Wu, J. C. 2019; 10
  • Induced Pluripotent Stem Cell-Based Cancer Vaccines. Frontiers in immunology Ouyang, X., Telli, M. L., Wu, J. C. 2019; 10: 1510

    Abstract

    Over a century ago, it was reported that immunization with embryonic/fetal tissue could lead to the rejection of transplanted tumors in animals. Subsequent studies demonstrated that vaccination of embryonic materials in animals induced cellular and humoral immunity against transplantable tumors and carcinogen-induced tumors. Therefore, it has been hypothesized that the shared antigens between tumors and embryonic/fetal tissues (oncofetal antigens) are the key to anti-tumor immune responses in these studies. However, early oncofetal antigen-based cancer vaccines usually utilize xenogeneic or allogeneic embryonic stem cells or tissues, making it difficult to tease apart the anti-tumor immunity elicited by the oncofetal antigens vs. graft-vs.-host responses. Recently, one oncofetal antigen-based cancer vaccine using autologous induced pluripotent stem cells (iPSCs) demonstrated marked prophylactic and therapeutic potential, suggesting critical roles of oncofetal antigens in inducing anti-tumor immunity. In this review, we present an overview of recent studies in the field of oncofetal antigen-based cancer vaccines, including single peptide-based cancer vaccines, embryonic stem cell (ESC)- and iPSC-based whole-cell vaccines, and provide insights on future directions.

    View details for DOI 10.3389/fimmu.2019.01510

    View details for PubMedID 31338094

    View details for PubMedCentralID PMC6628907

Footer Links:

Stanford Medicine Resources: